Literature DB >> 11328874

Identifying ribozyme-accessible sites using NUH triplet-targeting gapmers.

A A Mir1, T J Lockett, P Hendry.   

Abstract

Accurately identifying accessible sites in RNA is a critical prerequisite for optimising the cleavage efficiency of hammerhead ribozymes and other small nucleozymes. Here we describe a simple RNase H-based procedure to rapidly identify hammerhead ribozyme-accessible sites in gene length RNAS: Twelve semi-randomised RNA-DNA-RNA chimeric oligonucleotide probes, known as 'gapmers', were used to direct RNase H cleavage of transcripts with the specificity expected for hammerhead ribozymes, i.e. after NUH sites (where H is A, C or U). Cleavage sites were identified simply by the mobility of RNase H cleavage products relative to RNA markers in denaturing polyacrylamide gels. Sites were identified in transcripts encoding human interleukin-2 and platelet-derived growth factor. Thirteen minimised hammerhead ribozymes, miniribozymes (Mrz), were synthesised and in vitro cleavage efficiency (37 degrees C, pH 7.6 and 1 mM MgCl2) at each site was analysed. Of the 13 Mrz, five were highly effective, demonstrating good initial rate constants and extents of cleavage. The speed and accuracy of this method commends its use in screening for hammerhead-accessible sites.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11328874      PMCID: PMC37256          DOI: 10.1093/nar/29.9.1906

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  44 in total

Review 1.  Ribozymes: the characteristics and properties of catalytic RNAs.

Authors:  N K Tanner
Journal:  FEMS Microbiol Rev       Date:  1999-06       Impact factor: 16.408

2.  Numbering system for the hammerhead.

Authors:  K J Hertel; A Pardi; O C Uhlenbeck; M Koizumi; E Ohtsuka; S Uesugi; R Cedergren; F Eckstein; W L Gerlach; R Hodgson
Journal:  Nucleic Acids Res       Date:  1992-06-25       Impact factor: 16.971

3.  Extended target-site specificity for a hammerhead ribozyme.

Authors:  R Perriman; A Delves; W L Gerlach
Journal:  Gene       Date:  1992-04-15       Impact factor: 3.688

4.  Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library.

Authors:  A Lieber; M Strauss
Journal:  Mol Cell Biol       Date:  1995-01       Impact factor: 4.272

5.  3'-end labeling of RNA with recombinant yeast poly(A) polymerase.

Authors:  J Lingner; W Keller
Journal:  Nucleic Acids Res       Date:  1993-06-25       Impact factor: 16.971

6.  Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression.

Authors:  B P Monia; E A Lesnik; C Gonzalez; W F Lima; D McGee; C J Guinosso; A M Kawasaki; P D Cook; S M Freier
Journal:  J Biol Chem       Date:  1993-07-05       Impact factor: 5.157

7.  Generality of the NUX rule: kinetic analysis of the results of systematic mutations in the trinucleotide at the cleavage site of hammerhead ribozymes.

Authors:  T Shimayama; S Nishikawa; K Taira
Journal:  Biochemistry       Date:  1995-03-21       Impact factor: 3.162

8.  Prevention of human immunodeficiency virus type 1 integrase expression in Escherichia coli by a ribozyme.

Authors:  M Sioud; K Drlica
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

9.  Cytoplasmic delivery of ribozymes leads to efficient reduction in alpha-lactalbumin mRNA levels in C127I mouse cells.

Authors:  P J L'Huillier; S R Davis; A R Bellamy
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

10.  Accumulation of PDGF B and cell-binding forms of PDGF A in the extracellular matrix.

Authors:  J L Kelly; A Sánchez; G S Brown; C N Chesterman; M J Sleigh
Journal:  J Cell Biol       Date:  1993-06       Impact factor: 10.539

View more
  1 in total

1.  Tolerance for mutations and chemical modifications in a siRNA.

Authors:  Mohammed Amarzguioui; Torgeir Holen; Eshrat Babaie; Hans Prydz
Journal:  Nucleic Acids Res       Date:  2003-01-15       Impact factor: 16.971

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.